Mesoblast Ltd Total Liabilities
Mesoblast Ltd total liabilities. Based on the latest financial reports, Mesoblast Ltd (MESO) has total liabilities worth $204.67 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check asset resilience ratio of Mesoblast Ltd to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mesoblast Ltd (2005–2026)
Total liabilities of Mesoblast Ltd from 2005 to 2026. This chart illustrates how Mesoblast Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore how much of Mesoblast Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Mesoblast Ltd Competitors by Total Liabilities
The table below lists competitors of Mesoblast Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CleanSpark Inc
NASDAQ:CLSK
|
USA | $1.94 Billion |
|
Transportadora de Gas del Sur SA B
BA:TGSU2
|
Argentina | AR$2.70 Trillion |
|
Dermapharm Holding SE
XETRA:DMP
|
Germany | €1.54 Billion |
|
Grupo Profuturo S.A.B. de C.V
MX:GPROFUT
|
Mexico | MX$152.08 Billion |
|
Sarepta Therapeutics Inc
NASDAQ:SRPT
|
USA | $1.66 Billion |
|
Zhejiang Weixing New Building Materials Co Ltd
SHE:002372
|
China | CN¥1.39 Billion |
|
HCI Group Inc
NYSE:HCI
|
USA | $1.43 Billion |
Liability Composition Analysis (2005–2026)
This chart breaks down Mesoblast Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Mesoblast Ltd (MESO) total assets.
Liquidity & Leverage Metrics
Mesoblast Ltd Total Liabilities Ratios Explained
Mesoblast Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mesoblast Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mesoblast Ltd (2005–2026)
The table below shows the annual total liabilities of Mesoblast Ltd from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-06-30 | $204.67 Million | +9.31% |
| 2025-06-30 | $187.24 Million | -0.82% |
| 2024-06-30 | $188.80 Million | +12.66% |
| 2023-06-30 | $167.58 Million | +1.50% |
| 2022-06-30 | $165.10 Million | +1.09% |
| 2021-06-30 | $163.32 Million | -11.37% |
| 2020-06-30 | $184.28 Million | +7.72% |
| 2019-06-30 | $171.06 Million | +16.82% |
| 2018-06-30 | $146.44 Million | +5.41% |
| 2017-06-30 | $138.92 Million | -10.87% |
| 2016-06-30 | $155.86 Million | -61.85% |
| 2015-06-30 | $408.57 Million | +24.72% |
| 2014-06-30 | $327.60 Million | +29.26% |
| 2013-06-30 | $253.45 Million | +4.90% |
| 2012-06-30 | $241.61 Million | -2.34% |
| 2011-06-30 | $247.41 Million | +15406.41% |
| 2010-06-30 | $1.60 Million | +34.64% |
| 2009-06-30 | $1.19 Million | -24.65% |
| 2008-06-30 | $1.57 Million | +125.04% |
| 2007-06-30 | $698.90K | -84.19% |
| 2006-06-30 | $4.42 Million | +100.61% |
| 2005-06-30 | $2.20 Million | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid … Read more